Topics:
Gastrointestinal Cancers • Medical Oncology
Would you consider ivosidenib for a patient with metastatic cholangiocarcinoma and an IDH1 mutation following progression on gem/cis and FOLFOX?
Does the Child Pugh score factor in your treatment decision, i.e. Child Pugh score C?
Answer from: Medical Oncologist at Community Practice
The ideal situation would be enroll this refractory patient on a clinical trial. For example, the ClarIDHy study which is based on the promising phase II data of AG-120 in patients with IDH1 mutated cholangiocarcinoma. To treat the patient off-study, it can be challenging to get insurance approval, ...
Sign in or Register to read more